Improvements in patient‐reported outcomes in patients with psoriasis receiving etanercept plus topical therapies: results from REFINE

Papp, Kim; Barber, Kirk; Bissonnette, Robert; Bourcier, Marc; Lynde, Charles; Poulin, Yves; Shelton, Jennifer; Garces, Kirsten; Toole, John; Poulin‐Costello, Melanie

doi:10.1111/jdv.12934

Cited by 7 publications

(7 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Improvements in DLQI and Treatment Satisfaction Questionnaire for Medication scores in patients treated with etanercept 50 mg once weekly plus topical corticosteroid were equivalent to those in patients treated with 50 mg twice weekly in the 12-week extension period of the REFINE study. 65…”

Section: Reports From Clinical Trials and Case Studiesmentioning

confidence: 99%

A Review of Psoriasis, Therapies, and Suicide

Gooderham¹,

Gavino-Velasco

Clifford

et al. 2016

J Cutan Med Surg

View full text Add to dashboard Cite

Many chronic medical disorders are associated with psychiatric morbidity. Yet the psychological burden of these disorders often goes unnoticed. In dermatology, psoriasis has a higher association with psychiatric illness, including depression and suicide risk, compared with many other conditions. Studies suggest that effective treatment of psoriasis results in the improvement of psychiatric morbidity, particularly depression and anxiety. New biologic treatments for psoriasis may offer help beyond clearing of the skin in these patients and may lead to a reduction of psychiatric morbidity. Although concerns have been raised regarding the potential link between interleukin-17R blockade in the treatment of psoriasis and suicide, current literature provides no evidence to support this association.

show abstract

Section: Reports From Clinical Trials and Case Studiesmentioning

confidence: 99%

A Review of Psoriasis, Therapies, and Suicide

Gooderham¹,

Gavino-Velasco

Clifford

et al. 2016

J Cutan Med Surg

View full text Add to dashboard Cite

show abstract

“…However, after this point of time, a better response rate was observed in the adalimumab monotherapy group [46]. The REFINE study in 2015 compared the health-related quality of life (HRQoL) index for patients who received etanercept 50 mg twice a week versus those who used it with topical corticosteroids; the results for HRQoL were the same in both groups [47]. In our study, all the patients used additional topical treatments and the most frequent topical agents were corticosteroids (84.8%).…”

Section: Additional Psoriasis Treatment With Topical Medications Phomentioning

confidence: 99%

A Six-Year Analysis of Biological Therapy for Severe Psoriasis in a Lithuanian Reference Centre of Dermatovenereology

et al. 2020

View full text Add to dashboard Cite

Background and Objectives: Biological therapy is widely used for the treatment of severe psoriasis. The objective of this study was to evaluate the efficacy and safety of biological therapy for patients with severe psoriasis. Materials and Methods: A retrospective study of 79 patients with severe psoriasis, who have been treated with biological therapy between 2012 and 2018, was conducted. During this study, the following data were collected and evaluated: sex, age, body mass index (BMI), duration of illness, the results of treatment with biological therapy, concomitant therapy, Psoriasis Area and Severity Index (PASI) and adverse events. Results: In total, 74.7% (n = 59) of subjects were male. Their overall average age was 47.4 ± 11.4 (range: 18–73) years. Their baseline BMI was 27.6 ± 5.9, which increased to 29.6 ± 4.5 after 6 years of treatment. The mean duration of psoriasis was 25.7 ± 12.5 years. In total, 39.2% (n = 31) of subjects received infliximab, 36.7% (n = 29)—etanercept, 24.1% (n = 19)—ustekinumab. The treatment duration for infliximab, etanercept and ustekinumab was 201.6 ± 86.8, 156.2 ± 137.4 and 219.1 ± 95.7 weeks (p < 0.01), respectively. Overall, 65.8% (n = 52) of subjects were also on methotrexate; 30.8% (n = 16) of them discontinued it due to clinical improvement (31.3% (n = 5)), impaired liver function (31.3% (n = 5)), and intolerance (25% (n = 4)). Baseline PASI was 20.8 ± 8.8. PASI 50 was achieved by 96.2% (n = 76) of patients at week 11, PASI 75 by 86.1% (n = 68) at week 16, PASI 90 by 54.4% (n = 43) at week 35, and PASI 100 by 13.9% (n = 11) at week 33. The overall incidence rate of adverse events was 0.362 per patient year of follow-up. Conclusion: Biological therapy is an effective and safe treatment for patients with severe psoriasis.

show abstract

“…Furthermore, the beneficial effects exerted by apremilast on these psoriatic patients were independent from their baseline features, such as disease duration, PsA history, prior psoriasis therapies, or response to such therapies. Additional data from these trials revealed that apremilast has long term benefits on the skin and other psoriatic manifestations of these patients [ 74 , 76 , 78 ].…”

Section: Apremilast In Immune-mediated Inflammatory Disordersmentioning

confidence: 99%

PDE4 Inhibition and Inflammatory Bowel Disease: A Novel Therapeutic Avenue

Spadaccini

D’Alessio

Peyrin–Biroulet

et al. 2017

IJMS

View full text Add to dashboard Cite

Background. In the last few decades, a better knowledge of the inflammatory pathways involved in the pathogenesis of Inflammatory Bowel Disease (IBD) has promoted biological therapy as an important tool to treat IBD patients. However, in spite of a wider spectrum of biological drugs, a significant proportion of patients is unaffected by or lose their response to these compounds, along with increased risks of infections and malignancies. For these reasons there is an urgent need to look for new pharmacological targets. The novel Phosphodiesterase 4 (PDE4) inhibitors have been recently introduced as new modulators of intracellular signals and gene transcription for the treatment of IBD. Aim. To discuss and describe the state of the art of this new class of compounds in the IBD field, with particular attention to apremilast. Methods. Published articles selected from PubMed were comprehensively reviewed, with key words including apremilast, inflammatory disease, IBD, psoriasis, psoriatic arthritis, pathogenesis, therapies, and treatment. Results. PDE4 inhibitors generate elevated intracellular levels of cyclic Adenosine Monophosphate (cAMP), that consequently down-regulate the release of pro-inflammatory cytokines in the mucosa of IBD patients. The newly developed apremilast is one of these drugs and has already been approved for the treatment of dermatologic/rheumatologic inflammatory conditions; studies in psoriasis and psoriatic arthritis have in fact demonstrated its clinical activity. However, no clinical trials have yet been published on the use of apremilast in IBD. Conclusion. In light of the similarity of pro-inflammatory signaling pathways across the gut, the skin, and joints, apremilast is likely supposed to show its efficacy also in IBD.

show abstract

Improvements in patient‐reported outcomes in patients with psoriasis receiving etanercept plus topical therapies: results from REFINE

Cited by 7 publications

References 10 publications

A Review of Psoriasis, Therapies, and Suicide

A Review of Psoriasis, Therapies, and Suicide

A Six-Year Analysis of Biological Therapy for Severe Psoriasis in a Lithuanian Reference Centre of Dermatovenereology

PDE4 Inhibition and Inflammatory Bowel Disease: A Novel Therapeutic Avenue

Contact Info

Product

Resources

About